Cargando…

mTORC1 couples cyst(e)ine availability with GPX4 protein synthesis and ferroptosis regulation

Glutathione peroxidase 4 (GPX4) utilizes glutathione (GSH) to detoxify lipid peroxidation and plays an essential role in inhibiting ferroptosis. As a selenoprotein, GPX4 protein synthesis is highly inefficient and energetically costly. How cells coordinate GPX4 synthesis with nutrient availability r...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yilei, Swanda, Robert V., Nie, Litong, Liu, Xiaoguang, Wang, Chao, Lee, Hyemin, Lei, Guang, Mao, Chao, Koppula, Pranavi, Cheng, Weijie, Zhang, Jie, Xiao, Zhenna, Zhuang, Li, Fang, Bingliang, Chen, Junjie, Qian, Shu-Bing, Gan, Boyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7952727/
https://www.ncbi.nlm.nih.gov/pubmed/33707434
http://dx.doi.org/10.1038/s41467-021-21841-w
Descripción
Sumario:Glutathione peroxidase 4 (GPX4) utilizes glutathione (GSH) to detoxify lipid peroxidation and plays an essential role in inhibiting ferroptosis. As a selenoprotein, GPX4 protein synthesis is highly inefficient and energetically costly. How cells coordinate GPX4 synthesis with nutrient availability remains unclear. In this study, we perform integrated proteomic and functional analyses to reveal that SLC7A11-mediated cystine uptake promotes not only GSH synthesis, but also GPX4 protein synthesis. Mechanistically, we find that cyst(e)ine activates mechanistic/mammalian target of rapamycin complex 1 (mTORC1) and promotes GPX4 protein synthesis at least partly through the Rag-mTORC1-4EBP signaling axis. We show that pharmacologic inhibition of mTORC1 decreases GPX4 protein levels, sensitizes cancer cells to ferroptosis, and synergizes with ferroptosis inducers to suppress patient-derived xenograft tumor growth in vivo. Together, our results reveal a regulatory mechanism to coordinate GPX4 protein synthesis with cyst(e)ine availability and suggest using combinatorial therapy of mTORC1 inhibitors and ferroptosis inducers in cancer treatment.